Fludarabine
Nonmalignant Neoplasm
Asan Medical CenterSmall moleculePhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Nonmalignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ringer's acetate Joachim Zdolsek | Phase 4 | BB |
NORMAL HUMAN SERUM ALBUMIN Joachim Zdolsek | Phase 4 | BB |
Evomela Roswell Park Cancer Institute | Phase 2/3 | B |
Thiotepa Roswell Park Cancer Institute | Phase 2/3 | B |
Cyclophosphamide Roswell Park Cancer Institute | Phase 2/3 | B |
View all 16 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →